Ciusss de L'Est de l'Île de Montréal

ciusss-estmtl.gouv.qc.ca

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

88

Active

31

Phase 3

2

Total enrollment

24,062

Pipeline matrix

Showing 16 of 16 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Esmolol Hydrochloride1
Saline1
Melatonin1
Modified early post-operative intraperitoneal chemotherapy1
Transplant with an expanded ECT-001 cord blood1
ECT-001-CB1
Dexmedetomidine2
Ketamine Hydrochloride1
Dexmedetomidine Hydrochloride1
dexmedetomidine Hydrochloride and Ketamine Hydrochloride1
Programmed intermittent epidural bolus 5 ml1
Programmed intermittent epidural bolus 6 ml1
Programmed intermittent epidural bolus 7 ml1
Programmed intermittent epidural bolus 8 ml1
Programmed intermittent epidural bolus 9 ml1
Programmed intermittent epidural bolus 10 ml1

Next readouts

  • 2025-03-03
  • 2025-11
  • 2025-12-01
  • 2026-07
  • 2026-12-30
  • 2027-06
  • 2027-10
  • 2028-05

Top conditions

  • Anesthesia14
  • Nociceptive Pain4
  • Auditory Hallucination, Verbal3
  • Treatment-resistant Schizophrenia3
  • Chronic Pain3
  • Postoperative Pain3
  • Neuromuscular Blockade2
  • Viral Pneumonia2

Frequently asked questions about Ciusss de L'Est de l'Île de Montréal

How many clinical trials does Ciusss de L'Est de l'Île de Montréal have on ClinicalTrials.gov?
Ciusss de L'Est de l'Île de Montréal is listed as the lead sponsor on 88 clinical trials in ClinicalTrials.gov, 31 of which are currently active (recruiting, enrolling, or ongoing).
How many of Ciusss de L'Est de l'Île de Montréal's trials are in Phase 3?
2 of Ciusss de L'Est de l'Île de Montréal's trials are in Phase 3, spread across 16 active drug programs.
What therapeutic areas does Ciusss de L'Est de l'Île de Montréal focus on?
Ciusss de L'Est de l'Île de Montréal's most-studied conditions on ClinicalTrials.gov are Anesthesia, Nociceptive Pain, Auditory Hallucination, Verbal, Treatment-resistant Schizophrenia, Chronic Pain.
When are Ciusss de L'Est de l'Île de Montréal's next clinical trial readouts?
Ciusss de L'Est de l'Île de Montréal has 8 upcoming primary-completion readouts tracked here; the soonest is “Impact of Administration of Esmolol on Nociception Level-guided Control of Nociception.”, expected around 2025-03-03.